Patents by Inventor John Randall Sims, II

John Randall Sims, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods targeting interleukin-34
    Patent number: 11976114
    Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: May 7, 2024
    Assignee: ELI Lilly and Company
    Inventors: Marcio Chedid, Adam S. Fleisher, Megan Brittany Lannan, Albert Lo, Mark Mintun, Victor H. Obungu, Sarah Elisabeth Raines, John Randall Sims, II, Andrew Dixon Skora, Robin Elizabeth Walsh, Elizabeth Anne West, Ming Ye
  • ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF
    Publication number: 20240010713
    Abstract: The invention is directed to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-N3pGlu A? antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention, in some aspects, is related to doses and dosing regimens useful for such treatments. The invention is also related to, in some aspects, human subjects who are responsive to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-N3pGlu A? antibodies. The invention is also related to human subject who have one or two alleles of APOE4.
    Type: Application
    Filed: January 11, 2022
    Publication date: January 11, 2024
    Inventors: Adam S. FLEISHER, Mark MINTUN, John Randall SIMS, II, JonDavid SPARKS
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20230279094
    Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer’s Disease or a tauopathy disease.
    Type: Application
    Filed: October 27, 2022
    Publication date: September 7, 2023
    Inventors: Marcio Chedid, Adam S. Fleisher, Megan Brittany Lannan, Albert Lo, Mark Mintun, Victor H. Obungu, Sarah Elisabeth Raines, John Randall Sims, II, Andrew Dixon Skora, Robin Elizabeth Walsh, Elizabeth Anne West, Ming Ye
  • Combination Therapy
    Publication number: 20190046536
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-N3pGlu Abeta antibody selected from the group consisting of hE8L, Antibody I, and Antibody II.
    Type: Application
    Filed: March 8, 2017
    Publication date: February 14, 2019
    Inventors: Ronald Bradley DeMattos, Dustin James Mergott, John Randall Sims, II
  • COMBINATION THERAPY
    Publication number: 20190038613
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of (1r, 1?R,4R)-4-methoxy-5?-methyl-6?-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3?H-dispiro[cyclohexane-1,2?-indene-1?,2?-imidazol]-4?-amine, or a pharmaceutically acceptable salt thereof (including the camsylate salt thereof); in combination with an effective amount of an anti-N3pGlu Abeta antibody.
    Type: Application
    Filed: March 10, 2017
    Publication date: February 7, 2019
    Inventors: Ronald Bradley DeMattos, Patrick Cornelius May, John Randall Sims, II